These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 33178839)
1. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3 Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839 [TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma: the significance of CD8 Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502 [TBL] [Abstract][Full Text] [Related]
3. The significance of CD8 Zhu Q; Yang Y; Zeng Y; Chen K; Zhang Q; Wang L; Huang Y; Jian S Int Immunopharmacol; 2024 Aug; 137():112447. PubMed ID: 38909497 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenovirus decreases the proportion of TIM-3 Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929 [TBL] [Abstract][Full Text] [Related]
5. Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome. Wang X; Zhang T; Song Z; Li L; Zhang X; Liu J; Liu X; Qiu L; Qian Z; Zhou S; Feng L; Hu G; Meng B; Zhai Q; Ren X; Fu K; Li L; Wang P; Zhang H Int J Cancer; 2019 Sep; 145(5):1414-1422. PubMed ID: 30664812 [TBL] [Abstract][Full Text] [Related]
6. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma. Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma. Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635 [TBL] [Abstract][Full Text] [Related]
8. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma. Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222 [TBL] [Abstract][Full Text] [Related]
9. Low Distribution of TIM-3 Zhuang C; Ni B; Zhang ZZ; Zhao WY; Tu L; Ma XL; Yang LX; Cao H; Wang M J Immunol Res; 2021; 2021():6647292. PubMed ID: 33681387 [TBL] [Abstract][Full Text] [Related]
10. High levels of Tim-3 Zhong W; Liu X; Zhu Z; Li Q; Li K Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956 [TBL] [Abstract][Full Text] [Related]
11. Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma. Xiao T; Zhang L; Chen L; Liu G; Feng Z; Gao L Tumour Biol; 2014 Aug; 35(8):7951-6. PubMed ID: 24833097 [TBL] [Abstract][Full Text] [Related]
12. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. Pollari M; Pellinen T; Karjalainen-Lindsberg ML; Kellokumpu-Lehtinen PL; Leivonen SK; Leppä S Eur J Haematol; 2020 Dec; 105(6):712-721. PubMed ID: 32632935 [TBL] [Abstract][Full Text] [Related]
13. MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8 Xu Y; Liu Z; Lv L; Li P; Xiu B; Qian W; Liang A J Exp Clin Cancer Res; 2020 Nov; 39(1):238. PubMed ID: 33168024 [TBL] [Abstract][Full Text] [Related]
14. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma. Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619 [TBL] [Abstract][Full Text] [Related]
15. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549 [TBL] [Abstract][Full Text] [Related]
16. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448 [TBL] [Abstract][Full Text] [Related]
17. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434 [TBL] [Abstract][Full Text] [Related]
18. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8 Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227 [TBL] [Abstract][Full Text] [Related]
19. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. Gao X; Zhu Y; Li G; Huang H; Zhang G; Wang F; Sun J; Yang Q; Zhang X; Lu B PLoS One; 2012; 7(2):e30676. PubMed ID: 22363469 [TBL] [Abstract][Full Text] [Related]
20. Presence of Tim3 Klapholz M; Drage MG; Srivastava A; Anderson AC J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]